You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for IC 87201
IC 87201 is an inhibits binding of the NMDA receptor postsynaptic density protein 95 kDa (PSD95) to nNOS (EC50 = 23.94 μM), while not affecting the PSD95-ErbB4 interaction. Inhibits glutamate-induced cell death in cultured cortical neurons. Exhibits antinociceptive effects in inflammatory pain models in vivo. Also exhibits antidepressant-like activitiy in animal models.
Technical Data for IC 87201
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References for IC 87201
References are publications that support the biological activity of the product.
Doucet et al (2013) Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology. 38 1575 PMID: 23446451
Lee et al (2015) Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics. Neuropharmacology. 97 464 PMID: 26071110
Florio et al (2009) Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. Br.J.Pharmacol. 158 494 PMID: 19732061
View Related Products by Target
Keywords: IC 87201, IC 87201 supplier, IC87201, postsynaptic, density, protein, 95, PSD95, nNOS, NMDA, protein-protein, interactions, inhibitors, inhibits, binding, antinociceptive, antidepressant, Receptors, 6226, Tocris Bioscience
Citations for IC 87201
Citations are publications that use Tocris products.
Currently there are no citations for IC 87201.
Reviews for IC 87201
There are currently no reviews for this product. Be the first to review IC 87201 and earn rewards!
Have you used IC 87201?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Stem Cells
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.